Breaking Finance News

Gilead Sciences (NDAQ:GILD) has been downgraded from Buy to Hold in a statement by Argus earlier today.

Argus has downgraded Gilead Sciences (NDAQ:GILD) from Buy to Hold in a statement released on Monday November 13, 2017.

On 11/08/2017, Mizuho Securities released a statement on Gilead Sciences (NDAQ:GILD) upped the target price from $77.00 to $83.00 that suggested an upside of 0.14%.

Having a price of $72.86, Gilead Sciences (NDAQ:GILD) traded -0.47% lower on the day. With the last close up 11.79% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. GILD has recorded a 50-day average of $82.63 and a two hundred day average of $72.65. Trade Volume was down over the average, with 9,188,325 shares of GILD changing hands under the typical 9,443,500

Performance Chart

Gilead Sciences (NDAQ:GILD)

With a total market value of $0, Gilead Sciences has price-earnings ratio of 8.82 with a one year low of $63.76 and a one year high of $86.27 .

A total of 19 equity analysts have released a ratings update on GILD. Seven equity analysts rating the company a strong buy, nine equity analysts rating the company a buy, nine equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $111.05.

Brief Synopsis About Gilead Sciences (NDAQ:GILD)

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *